Seeking Alpha
View as an RSS Feed

Dr. Porter  

View Dr. Porter's Comments BY TICKER:
Latest  |  Highest rated
  • 4 Reasons Tonix Could Be A Multi-Bagger [View article]
    Outstanding article! Thank you very much.

    I fully agree with the long thesis, and for long term. I absolutely expect this product to be spectacularly successful in the marketplace.
    Dec 3, 2013. 11:04 AM | 2 Likes Like |Link to Comment
  • Recent FDA News Makes A Zalicus Trade Look Even More Compelling [View article]
    Mr. Ibrahim,

    Thank you for an informative, helpful article.

    I am long ZLCS based on solid, strong data to date as well as truly immense blockbuster potential.
    Oct 29, 2013. 12:00 PM | Likes Like |Link to Comment
  • DARA Raises Cash, Expands Sales Force [View article]
    Mr. Napodano,

    Thank you for another helpful article.

    I remain long DARA, encouraged by this 400% expansion of their sales force and the three complementary new products.
    Oct 28, 2013. 12:05 PM | 1 Like Like |Link to Comment
  • Will Apoptosis Succeed Where Other Cancer Treatments Haven't? Three Companies Trying [View article]
    Mr. Spiro,

    Thank you for a very well written article.
    I believe cancer-specific apoptotic agents hold great promise.
    Oct 25, 2013. 12:30 PM | 2 Likes Like |Link to Comment
  • Zalicus: An Upcoming Catalyst With Huge Potential [View article]
    Mr. Napodano,

    Thank you for an informative, helpful article.

    I am very optimistic on Z160 based on the strong data to date.

    Long ZLCS.
    Oct 24, 2013. 11:47 AM | Likes Like |Link to Comment
  • Why Zerenex Could Be More Than Just A Dialysis Product [View article]
    Mr. King,

    Thank you for an informative, helpful article.

    I believe Zerenex will sail through FDA approval and immediately become the standard-of-care in both dialysis and pre-dialysis patients. It is clearly superior to currently available phosphate binders, with the immense added benefit on iron levels. The decreased need for IV iron and expensive ESAs will make it very cost-effective.
    Oct 16, 2013. 02:53 PM | 3 Likes Like |Link to Comment
  • Agenus And Glaxo: Sizing Up The Potential For The RTS,S Malaria Vaccine [View article]
    Mr. Smith,

    Thank you for yet another excellent article.
    Oct 10, 2013. 11:51 AM | 2 Likes Like |Link to Comment
  • Tecfidera And The Revolution In Multiple Sclerosis Treatment [View article]
    Mr. Geschek,

    Thank you for yet another well-written, informative article.
    Oct 10, 2013. 10:54 AM | Likes Like |Link to Comment
  • pSivida: Previewing The Possible Effect On The Stock Of The October 17th PDUFA Date For Iluvien [View article]
    Mr. Smith,

    Thank you for another excellent article.

    The trial data on Iluvien is compelling, both safety and efficacy.

    I believe the probability of FDA approval is substantially greater than 60%.
    Oct 8, 2013. 08:11 AM | Likes Like |Link to Comment
  • Buy Plug Power Before October 1st [View article]
    Mr. Chase,

    Thank you for a very informative article.

    I see the same potential as you and am long PLUG.
    Sep 27, 2013. 12:41 PM | 2 Likes Like |Link to Comment
  • Biotech Chimerix Lock-Up Expiration [View article]
    Mr. Dion,

    Thank you for your informative article.

    I am long CMRX.

    The study published today in the New England Journal of Medicine is very well designed and executed and unequivocally establishes the safety and efficacy of brincidofovir.

    I anticipate brincidofovir, already in a Phase III trial, gaining broad usage against all five families of dsDNA viruses which include the herpesviruses and adenoviruses

    I believe the venture capital firms, executives and directors which own shares of CMRX recognize the immense potential of brincidofovir and will hold their stakes until far more of that potential is reflected in the share price.
    Sep 26, 2013. 11:51 AM | Likes Like |Link to Comment
  • Durata Therapeutics' Novel Antibiotic Makes It A Prime Takeover For 2013 [View article]
    Dalbavancin is clearly effective and safe.

    It is practically certain to be expeditiously approved, with the multiple, successful phase III trials run under SPA, plus QIDP designation.

    It will be a very welcome, much needed new antibiotic, active against MRSA.
    Aug 2, 2013. 12:52 PM | Likes Like |Link to Comment
  • For Zalicus, Z160 Data In October Could Be Huge [View article]
    Once again, thank you for your consistently excellent work!

    Long ZLCS.
    Aug 1, 2013. 02:25 PM | 1 Like Like |Link to Comment
  • Trius Therapeutics To Be Acquired By Cubist [View article]
    Mr. Smith,

    Another example of your excellent work.
    You deserve a victory lap!
    Thank you and keep it up!
    Jul 31, 2013. 09:03 AM | 2 Likes Like |Link to Comment
  • Significant Near-Term Catalyst Should Further Rally Keryx Pharmaceuticals [View article]
    Yes, I do agree.
    Jul 30, 2013. 09:08 AM | Likes Like |Link to Comment